Risk of Recurrent Urethral Stricture After Treatment With Paclitaxel-Coated Dilatation Balloon (Optilume) Compared With Non-coated Dilatation Balloon
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Optilume, UroMax Ultra.
- Who it may be relevant to
- Registry conditions: Urethral Stricture. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Risk of Recurrent Urethral Stricture After Treatment With Paclitaxel-Coated Dilatation Balloon (Optilume) Compared With Non-coated Dilatation Balloon - a Prospective Randomised Multicentre Study
Overview
Urethral strictures are often initially treated endoscopically with dilatation or direct visual internal urethrotomy (DVIU), a procedure where the stricture is incised through the vision of a cystoscope. These methods are easy to perform, they are often well tolerated under local anesthesia and they have a low risk of complications. One disadvantage is the relatively low success rate which is 20-60% when used as a first intervention and considerably lower after several interventions. Instead of repeated endoscopic procedures, it is advisable to perform open urethroplasty. Urethroplasty has a success rate of 65-91% but a higher risk of complications and requires general anesthesia. Therefore, there is a need for a treatment option for recurrent urethral strictures after DVIU or dilatation, before the urethroplasty is performed. Optilume is a CE-marked paclitaxel-coated dilatation balloon used for treatment of urethral strictures. The industry-sponsored randomised ROBUST III trial from 2022 showed a 75% success rate with Optilume but it is not sure if the results can be generalised to patients who would otherwise be candidates for open urethroplasty and whether the drug coating per se increases the efficacy of balloon dilatation. The aim of this study is to investigate whether the addition of paclitaxel-coating can increase the success rate and decrease the need for additional interventions and open urethroplasty for individuals who has a recurrent urethral stricture following at least one previous endoscopic intervention.
Interventions
- Combination product Optilume
Dilatation with drug-coated balloon - Device UroMax Ultra
Dilatation with non-coated balloon
Primary outcome measures
- Functional recurrent stricture [Time frame: Within 18 months of treatment]
Secondary outcome measures (4)
- Anatomical recurrent stricture [Time frame: Within 18 months of treatment]
- Qmax [Time frame: At 6 and 18 months after treatment]
- Time micturition [Time frame: At 6 and 18 months after treatment]
- Urethral Stricture Score [Time frame: At 6, 12 and 18 months after treatment]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
- Urethral stricture recurrence after at least one internal urethrotomy or dilatation
- Penile or bulbar stricture
- Length of stricture ≤ 2 cm
- Eligible for open urethroplasty
- Able to give informed consent
Exclusion criteria
- Stricture of the meatus
- Sclerosis of the bladder neck
- Multiple strictures < 16 Ch
- Complete stricture without any lumen
- Previous dilatation with paclitaxel-coated balloon
- Previous radiation therapy of the pelvis (e.g. for prostate cancer)
- Previous pelvic fracture
- Urethral malignancy
- Presence of urethral fistula
- Presence of urethral condyloma
- Previous open urethroplasty
- Chronic urinary retention secondary to detrusor inactivity
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Sweden · 4 centers
- Sahlgrenska University Hospital — Gothenburg
- Skåne University Hospital — Malmö
- Örebro University Hospital — Örebro
- Karolinska University Hospital — Stockholm
Identifiers
NCT: NCT06795074 · RUSTIC · CIV-24-12-050340